Baxter Gets Marketing Rights for Cangene's WinRho SDF in U.S.

Baxter Healthcare Corporation and Cangene Corporation announced that, effective immediately, Baxter has assumed exclusive rights to market and distribute Cangene's WinRho SDF [Rho(D) Immune Globulin Intravenous (Human)] in the United States. WinRho SDF is used to treat a critical bleeding disorder called immune thrombocytopenic purpura (ITP). Baxter currently markets WinRho SDF for Cangene in the UK and intends to launch the therapy in 10 other European countries, a Baxter release said.

Pharmabiz (http://www.pharmabiz.com/article/detnews.asp?articleid=26868§ionid=)